Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03463889 · ClinicalTrials.gov registry record · Phase 2
Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03463889 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 12 participants.
The verdict
NCT03463889, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well Gallium-68 prostate specific membrane antigen positron emission tomography (PET) work in diagnosing patients with thyroid cancer. Diagnostic procedures, such as 68Ga-PSMA PET, may more accurately diagnose thyroid cancer and find out how far the disease has spread.
Interventions
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Positron Emission Tomography (PET)
- DRUG Gallium Ga 68-labeled PSMA-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-03-19 |
| Est. Completion | 2020-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03463889
The ClinicalTrials.gov registry entry for NCT03463889 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT03463889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03463889 about?
NCT03463889 is a clinical study titled "Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer". This pilot clinical trial studies how well Gallium-68 prostate specific membrane antigen positron emission tomography (PET) work in diagnosing patients with thyroid cancer. Diagnostic procedures, such as 68Ga-PSMA PET, may more accurately diagnose thyroid cancer and find out how far the disease has ...
What is the current status of trial NCT03463889?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2018-03-19. Estimated completion is 2020-10-31.
What interventions are being tested in trial NCT03463889?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PET) (PROCEDURE), Gallium Ga 68-labeled PSMA-11 (DRUG).
Who is sponsoring clinical trial NCT03463889?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.